Department of Proteomics, Institute of Cellular Biology and Pathology "N. Simionescu" of the Romanian Academy, 050568 Bucharest, Romania.
Department of Pathophysiology, University of Medicine, Pharmacy, Sciences and Technology of Targu Mures, 540142 Targu Mures, Romania.
Int J Mol Sci. 2022 May 9;23(9):5289. doi: 10.3390/ijms23095289.
Prognosis after myocardial infarction (MI) varies greatly depending on the extent of damaged area and the management of biological processes during recovery. Reportedly, the inhibition of the pro-inflammatory S100A9 reduces myocardial damage after MI. We hypothesize that a S100A9 blockade induces changes of major signaling pathways implicated in post-MI healing. Mass spectrometry-based proteomics and gene analyses of infarcted mice left ventricle were performed. The S100A9 blocker (ABR-23890) was given for 3 days after coronary ligation. At 3 and 7 days post-MI, ventricle samples were analyzed versus control and Sham-operated mice. Blockade of S100A9 modulated the expressed proteins involved in five biological processes: , , , and . The blocker induced regulation of 36 proteins interacting with or targeted by the cellular tumor antigen p53, prevented myocardial compensatory hypertrophy, and reduced cardiac markers of post-ischemic stress. The blockade effect was prominent at day 7 post-MI when the quantitative features of the ventricle proteome were closer to controls. Blockade of S100A9 restores key biological processes altered post-MI. These processes could be valuable new pharmacological targets for the treatment of ischemic heart. Mass spectrometry data are available via ProteomeXchange with identifier PXD033683.
心肌梗死后(MI)的预后差异很大,这取决于受损区域的范围和恢复过程中生物过程的管理。据报道,抑制促炎 S100A9 可减少 MI 后的心肌损伤。我们假设 S100A9 阻断会引起与 MI 后愈合相关的主要信号通路的变化。对梗死小鼠左心室进行基于质谱的蛋白质组学和基因分析。在冠状动脉结扎后,给予 S100A9 阻断剂(ABR-23890)3 天。在 MI 后 3 天和 7 天,对心室样本进行分析,与对照和假手术小鼠进行比较。S100A9 阻断调节了涉及五个生物学过程的表达蛋白: 、 、 、 、 。阻断剂诱导了与细胞肿瘤抗原 p53 相互作用或靶向的 36 种蛋白的调节,防止了心肌代偿性肥大,并减少了缺血后应激的心脏标志物。在 MI 后 7 天,当心室蛋白质组的定量特征更接近对照时,阻断作用更为明显。S100A9 的阻断恢复了 MI 后改变的关键生物学过程。这些过程可能是治疗缺血性心脏病的有价值的新药理学靶点。质谱数据可通过 ProteomeXchange 以标识符 PXD033683 获得。